文献速递血栓与止血

膳食色氨酸增强癌症相关静脉血栓形成,吲哚胺2,3-双加氧酶1抑制可减轻

Dietary tryptophan augments cancer-associated venous thrombogenicity mitigated by indoleamine 2,3-dioxygenase 1 inhibition.
PubMed 文献 · Blood Adv · 2025-01-01

研究利用结肠癌-静脉血栓栓塞小鼠模型,发现富含蛋白质饮食增强荷瘤小鼠静脉血栓形成性,膳食色氨酸通过上调组织因子、纤溶酶原激活物抑制剂-1和血管性血友病因子及下调血栓调节蛋白诱导促凝静脉壁。靶向代谢组学显示荷瘤小鼠血清犬尿氨酸生成增加且分解受抑,犬尿氨酸水平与静脉血栓正相关。IDO1抑制剂降低血清犬尿氨酸、恢复静脉内皮促凝/抗凝因子平衡并显著抑制荷瘤小鼠静脉血栓形成性。

要点

  • 富含蛋白质饮食增强荷瘤小鼠静脉血栓形成性
  • 膳食色氨酸诱导促凝静脉壁,上调组织因子、纤溶酶原激活物抑制剂-1和血管性血友病因子,下调血栓调节蛋白
  • IDO1抑制剂降低血清犬尿氨酸并显著抑制荷瘤小鼠静脉血栓形成性

核心结论

  • 在同基因结肠癌模型中,富含蛋白质或色氨酸饮食具有促血栓形成效应,IDO1抑制剂可显著减轻该效应。

研究设计与样本

  • 利用新型结肠癌-静脉血栓栓塞小鼠模型进行实验研究。

主要发现

  • 不均衡的富含蛋白质饮食增强荷瘤小鼠静脉血栓形成性。
  • 膳食色氨酸诱导促凝静脉壁,表现为组织因子、纤溶酶原激活物抑制剂-1和血管性血友病因子上调及血栓调节蛋白下调。
  • 荷瘤小鼠血清靶向代谢组学显示犬尿氨酸生成增加且分解受抑,尽管所有组饮食消耗相同。
  • 犬尿氨酸水平与静脉血栓正相关。
  • 荷瘤小鼠血清和 Inferior vena cava 分别显示更高的 IDO1 活性和蛋白水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Studies related to cardio-oncology remain a high priority, considering that venous thromboembolism (VTE) in cancer survivors is the second most common cause of death. Although diet-derived metabolites are emerging as contributors to VTE, the influence of specific dietary components, their underlying mechanisms, and means to mitigate cancer-associated VTE remain poorly investigated. This point is important because population studies point to a protein-rich diet associated with VTE. Leveraging a new colon cancer-VTE mouse model, we show that an imbalanced protein-rich diet augments venous thrombogenicity in tumor-bearing mice. Further probing showed that dietary tryptophan induces a procoagulant venous wall, characterized by upregulation of tissue factor, plasminogen activator inhibitor-1, and von Willebrand factor and downregulation of thrombomodulin. Targeted metabolomics of sera from tumor-bearing mice revealed a pattern consistent with increased biogenesis of kynurenine (Kyn) and its suppressed catabolism, despite equal diet consumption in all groups. Kyn levels positively correlated with venous clots. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key rate-limiting enzyme converting tryptophan to Kyn. Sera and the inferior vena cava of tumor-bearing mice showed greater IDO1 activity and protein level, respectively. A specific IDO1 inhibitor reduced serum levels of Kyn, restored the balance of procoagulant and anticoagulant factors in the venous endothelium, and significantly suppressed venous thrombogenicity in tumor-bearing mice. Taken together, our results uncovered a prothrombotic effect of a protein- or tryptophan-rich diet in a syngeneic colon cancer model, which is significantly attenuated by an IDO1 inhibitor.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lotfollahzadeh S, Jose A, Yang X, et al. Dietary tryptophan augments cancer-associated venous thrombogenicity mitigated by indoleamine 2,3-dioxygenase 1 inhibition. Blood Adv. 2025. PMID: 40668615. doi:10.1182/bloodadvances.2025017079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。